Navigation Links
Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Date:1/15/2014

CAMBRIDGE, Mass., Jan. 15, 2014 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced initial results from its Phase 2a study of beloranib, a selective inhibitor of methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome (PWS), a severe form of genetic obesity.  These results showed improvements in body weight, hunger-related behaviors, and body composition, including reductions in body fat content and preserved lean body mass following four weeks of treatment. 

These changes were observed despite the increased caloric intake that was a component of this trial.  Known markers of beloranib response including those associated with cardiovascular disease risk were also improved, demonstrating that PWS patients responded to the molecular mechanism of beloranib.

"The results of this short-term proof-of-concept study are very promising and underscore our belief that beloranib has the potential to successfully treat this severe form of obesity.  To our knowledge, this study represents the largest placebo-controlled, randomized, multiple dose trial to date for obesity in this patient population, and these results bode well for further study of beloranib in patients with this devastating condition," said Thomas Hughes, Ph.D., President and Chief Executive Officer of Zafgen.

Similar to results seen in non-PWS obese patient populations, beloranib treatment in this study reduced body fat content by 8.1% vs. placebo in four weeks of treatment at the highest study dose of 1.8 mg, despite a 50% increased daily caloric allowance.  Hunger-related behaviors improved, and a trend towards overall improvement in body weight was seen, although this did not reach statistical significance, in part due to the fact that study was not powered to demonstrate these differ
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Zafgen Secures $21 Million in Series D Financing
3. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
4. Zafgen Secures $45 Million in Series E Financing
5. Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Showed Significantly Improved Functioning Within Three ... ... Nearly half of patients,with schizophrenia fail to remain on their medication ... from a new international,study showed that patients treated with risperidone long-acting ...
... Phase III Clinical Trial of Acetavance(TM) for the Treatment of ... ... Trial of Omigard(TM) Completes Patient Enrollment, SAN DIEGO, May ... company focused on in-licensing,developing and commercializing proprietary product candidates principally,for ...
Cached Medicine Technology:Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 2Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 3Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 4Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 5Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 6Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 2Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 3Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 4Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 5Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 6Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 7Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 8Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 9
(Date:7/10/2014)... According to a new market research report ... Naval), Application (Software Defined Radios, SATCOM, Encryption, Smartphones, ... Asia-Pacific, Europe, the Middle East & ROW) - ... market is estimated to be $30.15 billion in ... of 5.56% to reach $39.52 billion by 2019 ...
(Date:7/10/2014)... A Forever Recovery , an open-ended ... to a great start and gives them a solid ... a new Eating Disorders section of its website at ... , Different types of eating disorders listed ... (DSM-IV), including anorexia nervosa, bulimia nervosa, and EDNOS (Eating ...
(Date:7/10/2014)... electronic health record becomes widespread across the United States, ... Care Act, the quantity of clinical data that will ... dramatically increase. Additionally, experts in healthcare have become ... of data for the purpose of gleaning insights that ... care a process that is known as big ...
(Date:7/10/2014)... Teens who are sensitive to light or noise after ... such as anxiety and depression, a new study says. ... issues teens experience after concussion may help in planning ... when to return to play and what accommodations are ... Koehl and Dong Han, of the University of Kentucky ...
(Date:7/10/2014)... Dennis Thompson HealthDay Reporter ... out of 10 adults make use of calorie information on ... restaurants, according to a new U.S. study. Women in ... Seung Hee Lee-Kwan, an epidemiologist with the U.S. Centers for ... said they used menu labeling to help choose their meal, ...
Breaking Medicine News(10 mins):Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Some Teens May Face Emotional Problems After Concussion 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3
... Institute, a,leading healthcare career training provider, has announced John ... company,s board of directors.,Hopkins, currently the company,s chief executive ... during the board,s Feb. 4th meeting. , ... The consolidation of leadership roles ...
... (OTC Bulletin Board: MLSS), the recognized leader in advanced ... at the upcoming Chicago Dental Society,s 144th Midwinter Meeting ... sales of the STA Single Tooth Anesthesia System ... with four successive quarters of sales growth in 2008, ...
... babies and parents through the worst of teethingTHOUSAND OAKS, ... relief for their children, the options have been limited ... retailers who sell baby products have a groundbreaking therapeutic ... desperately seeking relief for their babies. The technology behind ...
... Provides Additional Free Resources to support Customer,s Weight ... leading provider of weight management products and services, ... with improved usability, new information architecture and visual ... that supports NutriSystem customers and new dieters to ...
... Physicians in Particular, According to New Report from ... a leading provider of managed care market intelligence, ... a number of challenges in the coming year, ... the new Orange County Market Overview , ...
... performing western blots -- a popular analytical technique used to ... ... CT (Vocus) February 23, 2009 -- Carestream Molecular Imaging, a ... for performing western blots -- a popular analytical ...
Cached Medicine News:Health News:MedVance Institute Promotes John L. Hopkins to Chairman of the Board of Directors 2Health News:Milestone Scientific to Exhibit at the Chicago Dental Society's 144th Midwinter Meeting 2Health News:Milestone Scientific to Exhibit at the Chicago Dental Society's 144th Midwinter Meeting 3Health News:Milestone Scientific to Exhibit at the Chicago Dental Society's 144th Midwinter Meeting 4Health News:Groundbreaking JeJe Teether Vibrates Pain Safely Away 2Health News:Groundbreaking JeJe Teether Vibrates Pain Safely Away 3Health News:NutriSystem.com Gets a Complete Makeover 2Health News:NutriSystem.com Gets a Complete Makeover 3Health News:NutriSystem.com Gets a Complete Makeover 4Health News:Regulations Against Balance Billing to Impact Orange County, Calif., Physicians' Bottom Line 2Health News:Carestream Molecular Imaging Releases Western Blot Kits For Added Convenience, Better Performance 2Health News:Carestream Molecular Imaging Releases Western Blot Kits For Added Convenience, Better Performance 3
Premium Full Color Digital Ultrasound...
... The new ACUSON CV70 cardiovascular ultrasound ... capabilities in a powerful, all-digital ultrasound ... sensitivity, color flow sensitivity and spatial ... the ACUSON family of cardiovascular products. ...
Aplio was designed for intuitive operation so you can get the results you are looking for quickly and easily. From customizable measurement packages to an ergonomic platform design, Aplio was built m...
AngioSpeed V series, it is an Angiography system designed for vascular treatment in various radiological regions, cardiology, and neurology. SHIMADZU brings you a single system with all units fused t...
Medicine Products: